OTC · NUGX
NuGenerex Immuno-Oncology, Inc.
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Aug 18, 2026, 10:36 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 10.03K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 1
- Avg. volume
- 114
Price performance
NUGX price history
1M range · 0 trading sessions · Daily adjusted prices
NUGX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NUGX news
The latest Smart Investors Daily articles mentioning NUGX.
Stock researchCompany · Overview
NUGX research
Overview
Company profile and research snapshot.
Company profile
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
